Hugo RAS

Medtronic (NYSE: MDT; founded 1949 in Minneapolis, with legal headquarters in Dublin) makes the Hugo robotic-assisted surgery system, the late-market big-medtech challenger to Intuitive's da Vinci. Hugo is a modular multi-port teleoperated platform that received its European CE mark for urologic and gynecologic procedures on October 11, 2021, and, in the key regulatory milestone, US FDA clearance on December 3, 2025 for urologic procedures only, including prostatectomy, nephrectomy, and cystectomy, backed by the Expand URO investigational-device-exemption trial of 137 patients that met its primary safety and efficacy endpoints and was presented at AUA 2025. General-surgery and gynecologic US indications are planned submissions but are not yet cleared. The registry records Hugo at commercial maturity: it has been CE-marked and commercially used outside the US across more than 30 countries since 2021 and is now US-cleared for urology and entering US rollout. Medtronic discloses no specific system installed-base count, citing only tens of thousands of procedures across 30-plus countries, so the unit count is left as an honest absence rather than invented. On AI substance, Hugo is a master-slave teleoperated system whose Touch Surgery digital and video ecosystem is analytics and recording rather than autonomy, with no verified shipped intraoperative AI guidance.

Yes. Hugo RAS is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Not verified as fully autonomous. Hugo RAS's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.

Hugo RAS is made by Medtronic, based in Dublin, Ireland, founded in 1949.

6 verified deployments of Hugo RAS are on the DEPLOY registry, including at United States (multiple hotel chains), Cleveland, United States.

Hugo RAS is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.

Hugo RAS has 2 regulatory records on the DEPLOY registry: FDA De Novo authorization, cleared; FDA 510(k) clearance (K250725), granted. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Hugo RAS include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Hugo RAS and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Hugo RAS has 6 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Hugo RAS ranks in roughly the top 5% of surgical models tracked by the registry.

Hugo RAS is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Hugo RAS has 7 active incidents on record in the DEPLOY registry. 7 incidents on record (2 serious, 3 moderate, 2 minor). Most recent: Jul 2026. Retracted incidents are excluded from this count.

Peer-reviewed studies show no significant differences in hospital stay length, blood loss, or complication rates between Hugo RAS and da Vinci Xi. Da Vinci has shorter docking and console times. Hugo RAS is Medtronic's challenger to Intuitive's da Vinci dominance, with a modular design and open architecture. Da Vinci remains the market leader with a much larger installed base.